Allogeneic stem cell transplantation for myelodysplastic syndromes in children: A Report from the spanish working party for blood and marrow transplantation in children (GETMON)

Pediatric Hematology and Oncology

Volumn 26, Issue 5, 2009, Pages 345-355

  Muñoz, Arturo ^a   Díaz Heredia, Cristina ^b   Badell, Isabel ^c   Bureo, Encarna ^d   Gómez, Pedro ^e   Martínez, Ana ^f   Verdeguer, Amparo ^g   Pérez Hurtado, José María ^h   Fernández Delgado, Rafael ⁱ   González Vicent, Marta ^j   Maldonado, María Soledad ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

more..

Author keywords

Allogeneic transplantation; Chimerism; Immunosupression; Myelodysplastic syndrome

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MELPHALAN; METHOTREXATE; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHILDHOOD DISEASE; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOPENIA; DISEASE COURSE; DONOR; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRESCHOOL CHILD; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY CYTOPENIA; RELAPSE; SCHOOL CHILD; SPAIN; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 68449098541     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010902976742     Document Type: Article

References (31)

1. Hasle H. Myelodysplastic and myeloproliferative disorders in children. Curr Opin Pediatr. 2007;19:1-8.
2. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277-282.
3. Barnard DR, Lange B, Alonzo TA, et al. Acute myeloid leukaemia and myelodysplastic syndrome in children treated for cancer: Comparison with primary presentation. Blood. 2002;100:427-434.
4. Woodward P, Barfield R, Hale G, et al. Outcome of hemopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukaemia or myelodysplastic syndrome. Pediatr Blood Cancer. 2006;47:931-935.
5. Sasaki H, Manabe A, Kojima S, et al. Myelodysplastic syndrome in childhood: A retrospective study of 189 patients in Japan. Leukemia. 2001;15:1713-1720.
6. Woods WG, Barnard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukaemia or myelodysplastic syndrome: A report from the Children's Cancer Group. J Clin Oncol. 2002;20:434-440.
7. Yusuf U, Fragoul HA, Gooley TA, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: The Seattle experience. Bone Marrow Transplant. 2004;33:805-814.
8. Trobaugh-Lotrario AD, Kletzel M, Quinones RR, et al. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): Successful management by allogeneic hemopoietic stem cell transplant (HSCT). Bone Marrow Transplant. 2005;35:143-149.
9. Bader P, Hoelle W, Klingebiel T, et al. Quantitative assessment of mixed hematopoietc chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res. 1996;16:1759-1763.
10. Sullivan KM. Graft versus host disease. In: Thomas ED, Blume KG, Forman SS, eds. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Scientific; 1999:513-536.
11. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc. 1957;53:457-481.
12. Stary J, Locatelli F, Niemeyer CM. Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant. 2005;35(Suppl 1):S13-S16.
13. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemias: A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110:620-630.
14. Kardos G, Baumann I, Passmore J, et al. Refractory anemia in childhood: A retrospective analysis of 67 patients with particular reference to monosomy 7. Blood. 2003;102:1997-2003.
15. Bader P, Niemeyer C, Willasch A, et al. Children with myelodysplastic syndrome (MDS) and mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy. Br J Haematol. 2005;128:649-658.
16. Castro-Malaspina H, Harris RE, Gajewsky J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943-1951.
17. Kalwak K, Wójcik D, Gorczynska E, et al. Allogeneic hemopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: Is that an alternative? Transplant Proc. 2004;36:1574-1577.
18. Sauter C, Barker JN. Unrelated donor umbilical cord transplantation for the treatment of hematologic malignancies. Curr Opin Hematol. 2008;15:568-575.
19. Guinan EC, Tarbell NJ, Trantavahi R, Weinstein HJ. Bone marrow transplantation for children with myelodysplastic syndrome. Blood. 1989;73:619-623.
20. Rune V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treament in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21:255-261.
21. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplatic syndromes. Blood. 1993;82:677-681.
22. Ebb DKH, Passmore SJ, Hann IM, et al. Results of treatment of children with refractory anemia with excess of blasts (RAEB) and RAEB in transformation (RAEB-t) in Great Britain, 1990-1999. Br J Haematol. 2002;117:33-39.
23. Creutzig U, Bender-Gotze C, Ritter J, et al. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t. Leukemia. 1998;12:652-659.
24. Niemeyer U, Duffner C, Bender-Gotze C, et al. AML-type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS), (Abstract). Blood. 2000;96:5212.
25. Skinner R, Velangi M, Bown M. Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. Pediatr Blood Cancer. 2008;50:670-672.
26. Bader P, Niemeyer C, Willasch A, et al. WT1 gene expression: Useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukaemia? Eur J Haematol. 2004;73:25-28.
27. Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M, Caballero D, San Miguel J. Chronic graft-versus-host disease: Pathogenesis and clinical management. Drugs. 2006;66:1041-1057.
28. Baron C, Somogyi R, Greller RD, et al. Predictor of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med. 2007;4:e23. doi: 10.1371/journal.pmed.0040023
29. Niemeyer CM, Kratz CP. Pediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: Molecular classification and treatment options. Br J Haematol. 2008;140:610-624.
30. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant. 2008;14:458-68.
31. Strahm B, Locatelli F, Bader P, et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant. 2007;40:329-333.